Aberrant overexpression of the wilms tumor gene (WT1) in human leukemia

• Published in: Blood Vol. 89; no. 4; pp. 1405 - 1412
• Main Authors: INOUE, K, OGAWA, H, TATEKAWA, T, SOMA, T, KISHIMOTO, T, SUGIYAMA, H, SONODA, Y, KIMURA, T, SAKABE, H, OKA, Y, MIYAKE, S, TAMAKI, H, OJI, Y, YAMAGAMI, T
• Format: Journal Article
• Language: English
• Published: Washington, DC The Americain Society of Hematology 15.02.1997
• Subjects: Acute Disease; Adult; Biological and medical sciences; Bone Marrow - pathology; Carcinogenesis, carcinogens and anticarcinogens; Cell Separation; DNA-Binding Proteins - biosynthesis; Fetal Blood - cytology; Flow Cytometry; Gene Expression Regulation, Leukemic; General aspects; Genes, Wilms Tumor; Hematopoietic Stem Cells - metabolism; Humans; Immunophenotyping; Infant, Newborn; Leukemia - genetics; Leukemia - metabolism; Leukemia - pathology; Lymphoma - genetics; Lymphoma - metabolism; Lymphoma - pathology; Medical sciences; Neoplasm Proteins - biosynthesis; Neoplasm Proteins - genetics; Neoplastic Stem Cells - metabolism; Transcription Factors - biosynthesis; Tumor Cells, Cultured; Tumors; WT1 Proteins; Human; Myeloproliferative syndrome; Chronic; Gene; Chronic myelocytic leukemia; Established cell line; Wilms tumor; Malignant hemopathy; Blast transformation; Gene expression; Carcinogenesis
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood.v89.4.1405

To clarify whether the expression of the WT1 gene in leukemic cells is aberrant or merely reflects that in normal counterparts, the expression levels of the WT1 gene were quantitated for normal hematopoietic progenitor cells. Bone marrow (BM) and umbilical cord blood (CB) cells were fluorescence-activated cell sorting (FACS)-sorted into CD34+ and CD34- cell populations, and the CD34+ cells into nine subsets (CD34+ CD33-, CD34+ CD33+, CD34+ CD38-, CD34+ CD38+, CD34+ HLA-DR-, CD34+ HLA-DR+, CD34+ c-kit(high), CD34+ c-kit(low), and CD34+ c-kit-) according to the expression levels of CD34, CD33, CD38, HLA-DR, and c-kit. Moreover, acute myeloid leukemic cells were also FACS-sorted into four populations (CD34+ CD33-, CD34+ CD33+, CD34- CD33+, and CD34- CD33-). FACS-sorted normal hematopoietic progenitor and leukemic cells and FACS-unsorted leukemic cells were examined for the WT1 expression by quantitative reverse transcriptase-polymerase chain reaction. The WT1 expression in the CD34+ and CD34- cell populations and in the nine CD34+ subsets of BM and CB was at either very low (1.0 to 2.4 x 10(-2)) or undetectable (< 10(-2)) levels (the WT1 expression level of K562 cells was defined as 1.0), whereas the average levels of WT1 expression in FACS-sorted and -unsorted leukemic cells were 2.4 to 9.3 x 10(-1). Thus, the WT1 expression levels in normal hematopoietic progenitor cells were at least 10 times less than those in leukemic cells. Therefore, we could not find any normal counterparts of BM or CB that expressed the WT1 at levels comparable with those in leukemic cells. These results indicate an aberrant overexpression of the WT1 gene in leukemic cells and imply the involvement of this gene in human leukemogenesis.